{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=25%25+human+albumin", "query": { "intervention": "25% human albumin" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 32, "total_pages": 4, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=25%25+human+albumin&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-29T10:51:56.587Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00949663", "title": "Xenin-25: Novel Regulator of Insulin Secretion and Beta-cell Function", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Type 2 Diabetes Mellitus" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "Glucose-dependent Insulinotropic Polypeptide (GIP)", "type": "DRUG" }, { "name": "Xenin-25", "type": "DRUG" }, { "name": "Glucose-dependent Insulinotropic Polypeptide plus Xenin-25", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 38, "start_date": "2009-10", "completion_date": "2014-02", "has_results": false, "last_update_posted_date": "2014-07-22", "last_synced_at": "2026-09-29T10:51:56.587Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT00949663" }, { "nct_id": "NCT04216784", "title": "Compare the Diuretic Effect With Furosemide vs Furosemide and Albumin Combined in Cirrhotic Patients", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Cirrhosis, Liver", "Volume Overload", "Fluid Overload" ], "interventions": [ { "name": "Furosemide Injection", "type": "DRUG" }, { "name": "Albumin Human", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Rush University Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 21, "start_date": "2019-12-19", "completion_date": "2024-04-01", "has_results": true, "last_update_posted_date": "2025-09-16", "last_synced_at": "2026-09-29T10:51:56.587Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT04216784" }, { "nct_id": "NCT01951716", "title": "Effects of Xenin-25 on Insulin Secretion and Gastric Emptying in Humans With and Without a Complete Truncal Vagotomy", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Does the Vagus Nerve Mediate the Effects of Xenin-25" ], "interventions": [ { "name": "Graded Glucose Infusion with Placebo", "type": "DRUG" }, { "name": "Graded Glucose Infusion with GIP Alone", "type": "DRUG" }, { "name": "Graded Glucose Infusion with xenin-25 alone", "type": "DRUG" }, { "name": "Graded Glucose Infusion with GIP plus xenin-25", "type": "DRUG" }, { "name": "Meal Tolerance Test with Placebo", "type": "DRUG" }, { "name": "Meal Tolerance Test with xenin-25", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 0, "start_date": "2013-01", "completion_date": "2018-07", "has_results": false, "last_update_posted_date": "2018-04-26", "last_synced_at": "2026-09-29T10:51:56.587Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT01951716" }, { "nct_id": "NCT01951729", "title": "The Role of Cholinergic Signaling for Mediating the Effects of GIP and/or Xenin-25 on Insulin Secretion", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Pre-diabetes" ], "interventions": [ { "name": "Control", "type": "DRUG" }, { "name": "Xenin-25 without atropine", "type": "DRUG" }, { "name": "GIP without atropine", "type": "DRUG" }, { "name": "Placebo with atropine", "type": "DRUG" }, { "name": "Xenin-25 with atropine", "type": "DRUG" }, { "name": "GIP with atropine", "type": "DRUG" }, { "name": "GIP plus Xenin-25 without atropine", "type": "DRUG" }, { "name": "GIP plus Xenin-25 with atropine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 15, "start_date": "2013-03-13", "completion_date": "2015-05", "has_results": false, "last_update_posted_date": "2018-05-25", "last_synced_at": "2026-09-29T10:51:56.587Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT01951729" }, { "nct_id": "NCT02910466", "title": "A Study of Extended Use of Recombinant Human Parathyroid Hormone (rhPTH(1-84)) in Hypoparathyroidism", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Chronic Hypoparathyroidism", "Hypoparathyroidism" ], "interventions": [ { "name": "rhPTH(1-84)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Shire", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "18 Years to 85 Years" }, "enrollment_count": 39, "start_date": "2016-10-27", "completion_date": "2019-12-20", "has_results": true, "last_update_posted_date": "2021-07-28", "last_synced_at": "2026-09-29T10:51:56.587Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02910466" }, { "nct_id": "NCT00220779", "title": "Immune Globulin Intravenous (IGIV) To Treat Relapsing, Remitting Multiple Sclerosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Sclerosis, Relapsing-Remitting" ], "interventions": [ { "name": "Immune Globulin IV [Human], 10% Caprylate/Chromatography Purified", "type": "DRUG" }, { "name": "Albumin (Human) 25%, United States Pharmacopeia (USP)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Grifols Therapeutics LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 128, "start_date": "2002-12", "completion_date": "2005-02", "has_results": true, "last_update_posted_date": "2016-04-27", "last_synced_at": "2026-09-29T10:51:56.587Z", "location_count": 6, "location_summary": "Phoenix, Arizona • Tucson, Arizona • New York, New York + 3 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "New York", "state": "New York" }, { "city": "Stony Brook", "state": "New York" }, { "city": "Winston-Salem", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00220779" }, { "nct_id": "NCT01031758", "title": "Reverse Cholesterol Transport (RCT) Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "3H-Cholesterol", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "University of Pennsylvania", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 18, "start_date": "2009-11", "completion_date": "2010-06", "has_results": false, "last_update_posted_date": "2018-12-20", "last_synced_at": "2026-09-29T10:51:56.587Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01031758" }, { "nct_id": "NCT02725060", "title": "Autoimmune Basis for Postural Tachycardia Syndrome", "overall_status": "ENROLLING_BY_INVITATION", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Postural Orthostatic Tachycardia Syndrome", "Postural Tachycardia Syndrome", "Tachycardia", "Arrhythmias, Cardiac", "Autonomic Nervous System Diseases", "Orthostatic Intolerance", "Cardiovascular Diseases", "Primary Dysautonomias" ], "interventions": [ { "name": "phenylephrine", "type": "DRUG" }, { "name": "isoproterenol", "type": "DRUG" }, { "name": "25 micro-Ci of radiation", "type": "RADIATION" }, { "name": "Posture study with blood samples", "type": "PROCEDURE" }, { "name": "24-hour heart rhythm and blood pressure monitoring", "type": "PROCEDURE" }, { "name": "Quantitative Axonal Sudomotor Reflex Testing", "type": "PROCEDURE" }, { "name": "Autonomic function tests", "type": "PROCEDURE" }, { "name": "Rebreathing test", "type": "OTHER" }, { "name": "Assessment of splanchnic capacitance", "type": "OTHER" }, { "name": "microneurography", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "RADIATION", "PROCEDURE", "OTHER" ], "sponsor": "Vanderbilt University Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 58, "start_date": "2016-02", "completion_date": "2026-12", "has_results": false, "last_update_posted_date": "2025-11-12", "last_synced_at": "2026-09-29T10:51:56.587Z", "location_count": 2, "location_summary": "Oklahoma City, Oklahoma • Nashville, Tennessee", "locations": [ { "city": "Oklahoma City", "state": "Oklahoma" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT02725060" }, { "nct_id": "NCT01019681", "title": "Efficacy and Safety of Umbilical Cord Blood Injection for Critical Limb Ischemia", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Critical Limb Ischemia" ], "interventions": [ { "name": "Cord blood stem cell injection", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Richard Burt, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "72 Years", "sex": "ALL", "summary": "18 Years to 72 Years" }, "enrollment_count": 1, "start_date": "2009-11", "completion_date": "2014-01", "has_results": false, "last_update_posted_date": "2014-02-03", "last_synced_at": "2026-09-29T10:51:56.587Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT01019681" }, { "nct_id": "NCT00543439", "title": "Study Evaluating Prophylaxis Treatment & Characterizing Efficacy, Safety, & PK Of B-Domain Deleted Recombinant FVIII", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hemophilia A" ], "interventions": [ { "name": "Moroctocog alfa (AF-CC)", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Months", "maximum_age": "15 Years", "sex": "MALE", "summary": "6 Months to 15 Years · Male only" }, "enrollment_count": 66, "start_date": "2007-12", "completion_date": "2018-04", "has_results": true, "last_update_posted_date": "2019-01-11", "last_synced_at": "2026-09-29T10:51:56.587Z", "location_count": 7, "location_summary": "Cincinnati, Ohio • Portland, Oregon • Dallas, Texas + 1 more", "locations": [ { "city": "Cincinnati", "state": "Ohio" }, { "city": "Portland", "state": "Oregon" }, { "city": "Portland", "state": "Oregon" }, { "city": "Dallas", "state": "Texas" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00543439" } ] }